Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29979350 | 1.00 | NLRP3 (0.45) | NLRP3ITGB3ITGA2BNPY1RTDP1 | |
| SCHEMBL23768812 | 0.91 | ITGB3 (0.43) | ITGB3ITGA2BNPY1RTDP1IDH1 | |
| SCHEMBL29979311 | 0.91 | ITGB3 (0.43) | ITGB3ITGA2BNPY1RTDP1IDH1 | |
| SCHEMBL29979318 | 0.91 | ITGB3 (0.51) | ITGB3ITGA2BTDP1 | |
| SCHEMBL23769073 | 0.91 | ITGB3 (0.51) | ITGB3ITGA2BTDP1 | |
| SCHEMBL25138340 | 0.90 | ITGB3 (0.45) | NLRP3ITGB3ITGA2BESR1MAOA | |
| SCHEMBL29978923 | 0.90 | ITGB3 (0.45) | NLRP3ITGB3ITGA2BESR1MAOA | |
| SCHEMBL23769034 | 0.89 | ITGB3 (0.47) | ITGB3ITGA2BNPY1RESR1 | |
| SCHEMBL29979316 | 0.89 | ITGB3 (0.47) | ITGB3ITGA2BNPY1RESR1 | |
| SCHEMBL25138402 | 0.88 | ESR1 (0.43) | ITGB3ITGA2BNPY1RESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151304-A | Small molecule interferon gene stimulating factor (STING) antagonists | 库拉德夫制药私人有限公司 | 2022-10-04 | — | — | CN | claimed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| WO-2021161230-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | NLRP3 25/4885ITGB3 2071/4885ITGA2B 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.